Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006244 · ClinicalTrials.gov registry record · Phase 2
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
A Phase 2 study of Refractory Multiple Myeloma and Stage III Multiple Myeloma, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00006244 is a Phase 2 study of Refractory Multiple Myeloma and Stage III Multiple Myeloma that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 36 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00006244, a Phase 2 study of Refractory Multiple Myeloma and Stage III Multiple Myeloma, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interleukin-2 (IL2) may stimulate a person's white blood cells to kill multiple myeloma cells. Interferon alfa may interfere with the growth of cancer cells
Conditions Studied
Interventions
- DRUG melphalan
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon alfa
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006244
The ClinicalTrials.gov registry entry for NCT00006244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (25% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which melphalan is the first listed.
NCT00006244 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00006244 about?
NCT00006244 is a clinical study titled "Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma". This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop g...
What is the current status of trial NCT00006244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2000-02. Estimated completion is 2016-04.
What conditions does trial NCT00006244 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage II Multiple Myeloma, Stage I Multiple Myeloma.
What interventions are being tested in trial NCT00006244?
The interventions under investigation include: melphalan (DRUG), aldesleukin (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00006244?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006244 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
RECRUITING · Phase 2
-
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
RECRUITING · Phase 2
-
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.